v3.26.1
INTANGIBLE UNDER DEVELOPMENT
 3 Months Ended 12 Months Ended
Mar. 31, 2026
Dec. 31, 2025
GNQ INSILICO INC [Member]    
Restructuring Cost and Reserve [Line Items]    
INTANGIBLE UNDER DEVELOPMENT

 

9.Intangible Under Development

INTANGIBLE UNDER DEVELOPMENT

a)Continuity of Capitalized Software Development Costs

 

The following table summarizes intangible assets:

 

   Drug
Assessment
Platform		   Bio Avatar
(formerly
Digital
Twins
Platform)		   Drug
Simulation
Platform		   Total 
Balance, January 1, 2025  $605,830   $14,806   $-   $620,636 
Additions: Capitalized costs   1,070,327    448,962    184,227    1,703,516 
Amortization   (69,553)   -         (69,553)
Balance, December 31, 2025  $1,606,604   $463,768   $184,227   $2,254,599 
Additions: Capitalized costs   150,056    186,401    27,000    363,457 
Amortization   (69,547)   -         (69,547)
Balance, March 31, 2026  $1,687,113   $650,169   $211,227   $2,548,509 

 

b)Amortization:

 

The amortization expense for the Drug Assessment Platform for the three months ended March 31, 2026 was $69,547 (March 31, 2025: nil).

 

c)Impairment:

 

At each balance sheet date, the Company compares the unamortized capitalized cost of each software product to its net realizable value (“NRV”), defined as estimated future gross revenues less estimated future costs of completing and disposing of the product. Any excess of unamortized cost over NRV is written off immediately and may not be subsequently restored. No impairment loss was recognized during the three months ended March 31, 2026 or the year ended December 31, 2025.

 

 

6.Intangible Under Development

INTANGIBLE UNDER DEVELOPMENT

a)Continuity of Capitalized Software Development Costs

 

The following table summarizes intangible assets:

 

   Drug Assessment Platform   Digital Twins Platform   Drug Simulation Platform   Total 
Balance, January 1, 2024   -    -    -    - 
Additions: Capitalized costs  $605,830   $14,806    -   $620,636 
Amortization   -    -    -    - 
Balance, December 31, 2024   605,830    14,806    -    620,636 
Additions: Capitalized costs   1,070,327    448,962   $184,227    1,703,516 
Amortization   (69,553)   -         (69,553)
Balance, December 31, 2025  $1,606,604   $463,768   $184,227   $2,254,599 

 

b)Amortization:

 

Capitalized software costs are amortized on a product-by-product basis commencing upon general release, using the greater of: (i) the ratio of current gross revenues to current and anticipated future gross revenues from the product; or (ii) the straight-line method over the remaining estimated economic life of the product. For the product, Drug Assessment Platform, the estimated useful life has been determined to be five years from the general release date of September 13, 2025. This platform is being enhanced, and the customers will be transitioned to the enhanced updated version.

 

The amortization expense for the year ended December 31, 2025 was $69,553 (2024: nil).

 

 

c)Impairment:

 

At each balance sheet date, the Company compares the unamortized capitalized cost of each software product to its net realizable value (“NRV”), defined as estimated future gross revenues less estimated future costs of completing and disposing of the product. Any excess of unamortized cost over NRV is written off immediately and may not be subsequently restored.